薬理ゲノミクスと薬理プロテオミクスのジャーナル

概要

Why Single Pharmacogenomic Trials Should be Very Significant?

Clive E Bowman

Recasting traditional frequentist thinking into Bayesian beliefs illustrates that requirements for 'strength of evidence' should drive the sizing of pharmacogenomic trials not hopeful hyperbolae. There is no 'free lunch' in pharmacogenomic investigations.